Serum Myokines Levels in Patients with Endogenous Cushing Syndrome and Acromegaly: Cross-Sectional Case−Control Study


Background: Myokines are produced and released by muscle cells in response to muscular contractions. Endogenous Cushing syndrome (CS) and acromegaly cause significant changes in muscle tissue leading to atrophy or hypertrophy. However, there is no data whether these endocrine abnormalities influence myokine secretion. 

Aims: To evaluate serum levels of myostatin, interleukin-6 (IL6) and irisin in patients with CS and acromegaly. 

Materials and methods: Fasting serum samples were taken and stored in aliquot at ≤-20°C from consecutive subjects with clinically evident and biochemically confirmed active CS, acromegaly and healthy volunteers matched by age, sex and body mass index (BMI). Commercially available kits were used to assay serum myokine levels. Grip strength was measured by a dynamometer. Insulin-like growth factor-1 (IGF1) was measured by immunochemiluminescence assay (Liaison), twenty-four hours urine free cortisol (24hUFC) ― by immunochemiluminescence assay (Vitros ECi), salivary free cortisol ― by electrochemiluminescence assay (Cobas). One-way ANOVA was utilized to assess the difference between groups. 

Results: We enrolled 88 subjects: 30 patients suffered from CS (group 1), 28 ― acromegaly (2) and 30 matched healthy controls (3) with no difference among the groups in sex, age and BMI (p=0.492, 0.062 and 0.174 respectively). Mean 24hUFC in subjects with CS and mean IGF1 in subjects with acromegaly were significantly higher as compared to other groups (p<0.001). Right-hand grip strength was lower in patients with CS as compared to both patients with acromegaly and healthy subjects (p=0.04). However, among these young adults we did not find statistically significant differences in measured myokines levels: irisin ― p=0.15; IL6 ― p=0.34; myostatin ― p=0.50. There was a significant correlation between myostatin and irisin in the whole group of people and in every separately analyzed subset of patients (p<0.001), but no correlation was found between any measured myokines and 24hUFC or IGF1.

Conclusions: Hypercortisolism or supraphysiological IGF1 levels do not significantly influence serum levels of myostatin, IL6 and irisin in young adults.

About the authors

T. T. Tsoriev

Endocrinology Research Centre, Moscow

Author for correspondence.

Аспирант отделения нейроэндокринологии и остеопатий 

Адрес: 117036, Москва, ул. Дмитрия Ульянова, д. 11

Russian Federation

Z. E. Belaya

Endocrinology Research Centre, Moscow

Доктор медицинских наук, главный научный сотрудник, заведующая отделением нейроэндокринологии и остеопатий Russian Federation

L. Y. Rozhinskaya

Endocrinology Research Centre, Moscow

Доктор медицинских наук, профессор, главный научный сотрудник отделения нейроэндокринологии и остеопатий Russian Federation

G. A. Melnitchenko

Endocrinology Research Centre, Moscow

Академик РАН, доктор медицинских наук, профессор, директор Института клинической эндокринологии Russian Federation

T. A. Grebennikova

Endocrinology Research Centre, Moscow

Клинический ординатор второго года обучения Russian Federation

A. V. Ilyin

Endocrinology Research Centre, Moscow

Заведующий клинико-диагностической лабораторией  Russian Federation

L. V. Nikankina

Endocrinology Research Centre, Moscow

Кандидат медицинских наук, ведущий научный сотрудник клинико-диагностической лаборатории Russian Federation

I. I. Dedov

Endocrinology Research Centre, Moscow

Академик РАН, доктор медицинских наук, профессор, директор Russian Federation


  1. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4):1379–1406. doi: 10.1152/physrev.90100.2007.
  2. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8(8):457–465. doi: 10.1038/nrendo.2012.49.
  3. Pratesi A, Tarantini F, Di Bari M. Skeletal muscle: an endocrine organ. Clin Cases Miner Bone Metab. 2013;10(1):11–14. doi: 10.11138/ccmbm/2013.10.1.011.
  4. Pedersen L, Hojman P. Muscle-to-organ cross talk mediated by myokines. Adipocyte. 2012;1(3):164–167. doi: 10.4161/adip.20344.
  5. Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr. 2002;132(11 Suppl):3456–3464.
  6. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(2):379–386. doi: 10.1158/1055-9965.EPI-07-0771.
  7. Hojman P, Dethlefsen C, Brandt C, et al. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metab. 2011;301(3):E504–510. doi: 10.1152/ajpendo.00520.2010.
  8. Allen DL, Hittel DS, McPherron AC. Expression and function of myostatin in obesity, diabetes, and exercise adaptation. Med Sci Sports Exerc. 2011;43(10):1828–1835. doi: 10.1249/MSS.0b013e3182178bb4.
  9. Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14(1):58–74. doi: 10.1038/nrd4467.
  10. Rana KS, Arif M, Hill EJ, et al. Plasma irisin levels predict telomere length in healthy adults. Age (Dordr). 2014;36(2):995–1001. doi: 10.1007/s11357-014-9620-9.
  11. Белая Ж.Е., Рожинская Л.Я., Драгунова Н.В., и др. Метаболические осложнения эндогенного гиперкортицизма. Выбор пациентов для скрининга // Ожирение и метаболизм. — 2013. — №1. — С. 26–31. [Belaya ZE, Rozhinskaya LY, Dragunova NV, et al. Metabolic complications of endogenous Cushing: patient selection for screening. Obesity and metabolism. 2013;(1):26-31. (In Russ).] doi: 10.14341/2071-8713-5068.
  12. Драгунова Н.В., Белая Ж.Е., Рожинская Л.Я. Состояние костно-мышечной системы при эндогенном гиперкортицизме // Остеопороз и остеопатии. — 2012. — №3. — С. 18–24. [Dragunova NV, Belaya ZE, Rozhinskaya LY. Musculoskeletal system in the endogenous hypercortisolism. Osteoporosis and osteopathy. 2012;(3):18–24. (In Russ).].
  13. Потешкин Ю.Е., Пронин В.С., Мельниченко Г.А., и др. Влияние избытка гормона роста и ИФР-1 на костно-суставную систему при акромегалии // Актуальная эндокринология. — 2015. — №10. — С. 1–30. [Poteshkin YE, Pronin VS, Melnichenko GA, et al. Growth hormone and IGF-1 effects on articular and skeletal system in acromegaly. Aktual’naya endokrinologiya. 2015;(10):1–30. (In Russ).] doi: 10.18508/endo3539.
  14. Halse J, Haugen HN. Calcium and phosphate metabolism in acromegaly. Acta Endocrinol (Copenh). 1980;94(4):459–467.
  15. Borg SA, Kerry KE, Baxter L, et al. Expression of interleukin-6 and its effects on growth of HP75 human pituitary tumor cells. J Clin Endocrinol Metab. 2003;88(10):4938–4944. doi: 10.1210/jc.2002-022044.
  16. Shyu KG, Ko WH, Yang WS, et al. Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;68(3):405–414. doi: 10.1016/j.cardiores.2005.06.028.
  17. Gaussin V, Depre C. Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res. 2005;68(3):347–349. doi: 10.1016/j.cardiores.2005.09.007.
  18. Demirpence M, Yilmaz H, Colak A, et al. The effect of sleeve gastrectomy on serum irisin levels in patients with morbid obesity. Endokrynol Pol. 2016. doi: 10.5603/EP.a2016.0029.
  19. Polyzos SA, Kountouras J, Anastasilakis AD, et al. Irisin in patients with nonalcoholic fatty liver disease. Metabolism. 2014;63(2):207–217. doi: 10.1016/j.metabol.2013.09.013.
  20. Li L, Rampersad S, Wang X, et al. Serum irisin concentrations were increased after transient continuous subcutaneous insulin infusion in type 2 diabetes mellitus patients. Diabetes Res Clin Pract. 2016;113:44–47. doi: 10.1016/j.diabres.2016.01.030.
  21. Белая Ж.Е., Смирнова О.М., Дедов И.И. Роль физических нагрузок в норме и при сахарном диабете // Проблемы эндокринологии. — 2005. — Т. 51. — №2. — С. 28–37. [Belaya ZE, Smirnova OM, Dedov II. Rol’ fizicheskikh nagruzok v norme i pri sakharnom diabete. Probl Endokrinol (Mosc). 2005;51(2):8–37. (In Russ).]
  22. Garcia-Fontana B, Reyes-Garcia R, Morales-Santana S, et al. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state? Endocrine. 2016;52(1):54–62. doi: 10.1007/s12020-015-0758-8.

Supplementary files

There are no supplementary files to display.

Copyright (c) 2016 "Paediatrician" Publishers LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies